TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15184095

Group type: EXPERIMENTAL
Intervention: Mental arithmetic with harassment followed by cold pressor (MA/CP)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cold pressor followed by mental arithmetic (CP/MA)
Number of subjects: 53
Study: 11125190

Group type: EXPERIMENTAL
Intervention: Tunnel preparation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Class II cavity preparation
Number of subjects: 60
Study: 9329638

Group type: EXPERIMENTAL
Intervention: Comet assay (single‐cell gel electrophoresis) for measuring DNA strand breaks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified comet assay with lesion‐specific endonuclease for DNA base oxidation
Number of subjects: 0
Study: 8356846

Group type: EXPERIMENTAL
Intervention: Trivalent CR vaccine (A H1N1 (CR‐125), A H3N2 (CR‐149), and B (CRB‐117))
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bivalent CR vaccine (CR‐125 and CR‐149)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Monovalent CRB‐117
Number of subjects: 71

Group type: COMPARATOR
Intervention: Inactivated split vaccine
Number of subjects: 71
Study: 3437376

Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg orally administered)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 2399425

Group type: EXPERIMENTAL
Intervention: Zinc/triclosan dentifrice (0.5% zinc citrate and 0.2% triclosan) for 6 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Zinc/triclosan dentifrice (0.5% zinc citrate and 0.2% triclosan)
Number of subjects: 101
Study: 1091686

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH) 100 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31424156

Group type: EXPERIMENTAL
Intervention: Dpy19l2-deficient human globozoospermia
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normozoospermia (control)
Number of subjects: 6
Study: 28151878

Group type: EXPERIMENTAL
Intervention: Music playback during stepping-in-place training
Number of subjects: 11

Group type: COMPARATOR
Intervention: Radio podcast playback during stepping-in-place training
Number of subjects: 11
Study: 26141203

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program
Number of subjects: 91

Group type: COMPARATOR
Intervention: Wellness standard of care comparison group
Number of subjects: 91
Study: 23870717

Group type: EXPERIMENTAL
Intervention: Pay for Performance (P4P) programme
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 1500
Study: 22258771

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam/Ketamine
Number of subjects: 60
Study: 19333103

Group type: EXPERIMENTAL
Intervention: Clinician readings
Number of subjects: 396

Group type: COMPARATOR
Intervention: Radiologist readings
Number of subjects: 396
Study: 16502156

Group type: EXPERIMENTAL
Intervention: Guided fantasy present
Number of subjects: 215

Group type: COMPARATOR
Intervention: Guided fantasy absent
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Exposure duration
Number of subjects: 215
Study: 15553010

Group type: COMPARATOR
Intervention: Protocol A (fixed injection rate of 2.0 mL/sec with a 70 sec delay)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Protocol B (80% of contrast in 40 sec, remaining 20% in 20 sec with an 80 sec delay)
Number of subjects: 60
Study: 10943748

Group type: EXPERIMENTAL
Intervention: Deep peroneal nerve stimulation
Number of subjects: 10
Study: 9398090

Group type: EXPERIMENTAL
Intervention: Epicardial implantable cardioverter defibrillator (ICD)
Number of subjects: 900

Group type: COMPARATOR
Intervention: No antiarrhythmic treatment (Control)
Number of subjects: 900
Study: 8417877

Group type: EXPERIMENTAL
Intervention: Theophylline (300 mg sustained-release, four doses at 12-hour intervals)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3091717

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) (1 g t.i.d.)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 100
Study: 31667747

Group type: EXPERIMENTAL
Intervention: Yoga classes (12 weekly sessions)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT) sessions (1-on-1)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Pain improvement (≥30% at 6 weeks)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Physical function improvement (≥30% at 6 weeks)
Number of subjects: 320
Study: 29763832

Group type: EXPERIMENTAL
Intervention: Regular pain assessment using the Doloplus-2 scale twice a week for 12 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 112
Study: 27175574

Group type: EXPERIMENTAL
Intervention: website-tailored
Number of subjects: 235

Group type: COMPARATOR
Intervention: website-unstructured
Number of subjects: 235
Study: 25759402

Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caffeine (both doses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 23006505

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training (3 days/week for 30 min at 65-85% of peak oxygen uptake for aerobic; 2 days/week for resistance training with 9 exercises at 12-repetition-maximum)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 25
Study: 21074284

Group type: EXPERIMENTAL
Intervention: Yoghurt
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Capsules
Number of subjects: 36

Group type: COMPARATOR
Intervention: Yoghurt and Cheese
Number of subjects: 36

Group type: COMPARATOR
Intervention: All product groups
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: P. freudenreichii subsp. shermanii JS and B. animalis subsp. lactis Bb12
Number of subjects: 36
Study: 19213349

Group type: EXPERIMENTAL
Intervention: Sanjie Zhentong Capsule (SJC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Temporization (Control)
Number of subjects: 58
Study: 16641447

Group type: EXPERIMENTAL
Intervention: Cefditoren-pivoxil 200 mg twice daily for 5 days
Number of subjects: 541

Group type: COMPARATOR
Intervention: Cefuroxime-axetil 250 mg twice daily for 10 days
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Cefditoren-pivoxil
Number of subjects: 541

Group type: COMPARATOR
Intervention: Cefuroxime-axetil
Number of subjects: 541
Study: 11959766

Group type: EXPERIMENTAL
Intervention: 5 ml 0.5% bupivacaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: 5 ml 0.9% saline
Number of subjects: 68
Study: 9585794

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 to 40 mg/day) + Moclobemide (up to 600 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fluoxetine (20 to 40 mg/day)
Number of subjects: 18
Study: 8537616

Group type: EXPERIMENTAL
Intervention: Psychological intervention, details not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 2295949

Group type: EXPERIMENTAL
Intervention: Cow milk
Number of subjects: 52

Group type: COMPARATOR
Intervention: Milk-based formula
Number of subjects: 52
Study: 85322

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CHOP + BCG)
Number of subjects: 669

Group type: COMPARATOR
Intervention: Chemotherapy alone (CHOP + bleomycin or COP + bleomycin)
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Maintenance BCG
Number of subjects: 669

Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 669
Study: 30935257

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 1640
Study: 31208435

Group type: EXPERIMENTAL
Intervention: Weight bearing functional exercise
Number of subjects: 128

Group type: COMPARATOR
Intervention: Non-weight bearing quadriceps strengthening exercise
Number of subjects: 128
Study: 30355790

Group type: EXPERIMENTAL
Intervention: Subcutaneous treatment with bemiparin 3500 IU/0.2 mL/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27096869

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (MIE, 60% VO2MAX)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HIE, 85% VO2MAX)
Number of subjects: 15
Study: 24702571

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine plus dexmedetomidine administration (Phase M+D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrathecal morphine administration (Phase M)
Number of subjects: 0
Study: 21621958

Group type: EXPERIMENTAL
Intervention: Tibial screws used in tibial baseplate fixation
Number of subjects: 154

Group type: COMPARATOR
Intervention: Screwless tibial baseplate fixation
Number of subjects: 154
Study: 20639797

Group type: COMPARATOR
Intervention: Abdominoplasty without quilting sutures (Group A)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Abdominoplasty with quilting sutures (Group B)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lipoabdominoplasty (Group C)
Number of subjects: 58
Study: 17666461

Group type: EXPERIMENTAL
Intervention: Self-management course
Number of subjects: 196

Group type: COMPARATOR
Intervention: Intensive medical treatment
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Combination of intensive medical treatment and self-management course
Number of subjects: 196
Study: 15723977

Group type: EXPERIMENTAL
Intervention: sirolimus‐eluting stents
Number of subjects: 238

Group type: COMPARATOR
Intervention: bare‐metal stents
Number of subjects: 238
Study: 11928027

Group type: COMPARATOR
Intervention: Outpatient group (discharged after 4 hours)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Inpatient group (admitted overnight)
Number of subjects: 80
Study: 9866070

Group type: EXPERIMENTAL
Intervention: Pulsing centrifugation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard centrifugation
Number of subjects: 10
Study: 7608322

Group type: EXPERIMENTAL
Intervention: Intravenous administration (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled administration (2 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments (Intravenous, Oral, Inhaled)
Number of subjects: 0
Study: 2231488

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 14
Study: 323443

Group type: EXPERIMENTAL
Intervention: Naloxone, 0.01 mg/kg intramuscularly
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30859302

Group type: EXPERIMENTAL
Intervention: Postoperative ROM
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Preoperative laxity
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Postoperative laxity
Number of subjects: 204

Group type: COMPARATOR
Intervention: Balanced vs. unbalanced groups
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Total laxity
Number of subjects: 204
Study: 28588168

Group type: EXPERIMENTAL
Intervention: Rapid advancement group (15ml/kg/day for 1000-<1250g; 20ml/kg/day for 1250-<1500g)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Slow advancement group (10ml/kg/day for 1000-<1250g; 15ml/kg/day for 1250-<1500g)
Number of subjects: 95
Study: 26419681

Group type: EXPERIMENTAL
Intervention: Extract of Daikenchuto (TJ-100)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 24124985

Group type: EXPERIMENTAL
Intervention: Visualisation combined with health message (first-person perspective)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Visualisation combined with health message (third-person perspective)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Visualisation without health message
Number of subjects: 532

Group type: COMPARATOR
Intervention: Health message only (no visualisation)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Visualisation (irrespective of perspective) with health message
Number of subjects: 532
Study: 21083558

Group type: EXPERIMENTAL
Intervention: Dysport-240
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 19185241

Group type: EXPERIMENTAL
Intervention: HumanOptics MC611MI microincision IOL
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alcon AcrySof MA60AC 3‐piece IOL
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Alcon AcrySof MA60AC 3‐piece IOL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 32
Study: 17335317

Group type: EXPERIMENTAL
Intervention: Topiramate (started at 25 mg/day, titrated to 400 mg/day or maximum tolerated dose)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 15367052

Group type: EXPERIMENTAL
Intervention: Paroxetine plus 12 sessions of CBT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Paroxetine only
Number of subjects: 35
Study: 11583498

Group type: EXPERIMENTAL
Intervention: Home inflation of tissue expanders
Number of subjects: 23

Group type: COMPARATOR
Intervention: Outpatient inflation of tissue expanders
Number of subjects: 23
Study: 9523369

Group type: EXPERIMENTAL
Intervention: Adjusted DLCOsb values after applying corrections for VD, carbon dioxide, hemoglobin, and carboxyhemoglobin
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Correction for VD
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: All corrections considered
Number of subjects: 1214

Group type: EXPERIMENTAL
Intervention: Correction for Hb
Number of subjects: 1214
Study: 1895265

Group type: EXPERIMENTAL
Intervention: Phone intervention
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Clinic intervention
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Both phone and clinic intervention
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 439
Study: 6762370

Group type: EXPERIMENTAL
Intervention: L‐carnitine (1.2‐1.8 g/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31362119

Group type: EXPERIMENTAL
Intervention: Double negative for HBV DNA and RNA at the end of treatment (evaluation cohort)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Positive for either HBV DNA or RNA at the end of treatment (evaluation cohort)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Double negative for HBV DNA and RNA at the end of treatment (validation cohort)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Positive for either HBV DNA or RNA at the end of treatment (validation cohort)
Number of subjects: 130
Study: 30699846

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3 g/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 28342061

Group type: EXPERIMENTAL
Intervention: Obinutuzumab in combination with chlorambucil (GClb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab in combination with chlorambucil (RClb)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil alone (Clb)
Number of subjects: 0
Study: 27423373

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavioural therapy (CBT‐E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced cognitive behavioural therapy (CBT‐E) and Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study: 25591521

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study: 22909345

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 382
Study: 20485039

Group type: EXPERIMENTAL
Intervention: Modified maxillary protraction appliance (MMPA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Bimaxillary surgery (BMS)
Number of subjects: 26
Study: 18538401

Group type: EXPERIMENTAL
Intervention: Half-dose verteporfin photodynamic therapy (PDT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 15800144

Group type: EXPERIMENTAL
Intervention: PROSPECT intervention (care management model with trained care managers providing algorithm-based recommendations and treatment adherence support over 18 months)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: PROSPECT intervention
Number of subjects: 215
Study: 12446281

Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10559522

Group type: EXPERIMENTAL
Intervention: 375 ml of red wine (30 g alcohol) per day for 2 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: White wine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Red grape juice
Number of subjects: 7
Study: 9170760

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 94
Study: 7505360

Group type: EXPERIMENTAL
Intervention: Losartan (20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3083458

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30085177

Group type: EXPERIMENTAL
Intervention: Allostatic load (AL) score
Number of subjects: 836
Study: 26590199

Group type: EXPERIMENTAL
Intervention: Pre-Anesthetic Induction Patient Safety (PIPS) checklist embedded in Anesthesia Information Management System (AIMS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No checklist
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pre-Anesthetic Induction Patient Safety (PIPS) checklist
Number of subjects: 38
Study: 25323030

Group type: EXPERIMENTAL
Intervention: Provision of school meals rich in fish, vegetables, and fibre
Number of subjects: 834

Group type: COMPARATOR
Intervention: Usual packed lunch from home (control)
Number of subjects: 834
Study: 22492382

Group type: EXPERIMENTAL
Intervention: RUCF (fortified soybean-maize-sorghum paste)
Number of subjects: 1383

Group type: COMPARATOR
Intervention: UNIMIX (fortified corn soy blend porridge)
Number of subjects: 1383
Study: 21744761

Group type: EXPERIMENTAL
Intervention: Lidocaine 2.0% (intravenous bolus 1.5 mg/kg followed by an infusion of 1.5 mg/kg/h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 19089209

Group type: EXPERIMENTAL
Intervention: Chemomechanical method (Carisolv; MediTeam)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 50
Study: 15953979

Group type: EXPERIMENTAL
Intervention: Minimal intervention (verbal information on the Medicaid pharmacotherapy benefit)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Self Help (verbal information plus self‐help information materials)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Case Management (verbal information, self‐help information, plus case management assistance)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 608
Study: 11915973

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 424

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 424
Study: 10423024

Group type: EXPERIMENTAL
Intervention: Late menarche (>14 years)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Early menarche (<12 years)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Adjustment for weight
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Age at menarche
Number of subjects: 169
Study: 7671177

Group type: EXPERIMENTAL
Intervention: Home program of aerobic training (intensity gradually increasing from 1.5 to 4.0 METs) for 8 weeks starting at discharge.
Number of subjects: 80

Group type: COMPARATOR
Intervention: General guidelines for progressive increase of activity level (Control group).
Number of subjects: 80
Study: 1954069

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oxazepam (15 mg)
Number of subjects: 14
Study: 7272163

Group type: EXPERIMENTAL
Intervention: Caroxazone 300 mg/day for 12 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caroxazone 600 mg/day for 12 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tranylcypromine 20 mg/day for 8 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine 50 mg/day for 12 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caroxazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tranylcypromine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caroxazone 300 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caroxazone 600 mg/day
Number of subjects: 0
Study: 30391759

Group type: EXPERIMENTAL
Intervention: Intravenous administration of Tranexamic Acid (TXA)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Topical administration of Tranexamic Acid (TXA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 126
Study: 28200045

Group type: EXPERIMENTAL
Intervention: Single-dose regimen of Benzathine Penicillin G (2.4 million units)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 3-dose regimen of Benzathine Penicillin G
Number of subjects: 64
Study: 25389044

Group type: EXPERIMENTAL
Intervention: Patent Blue dye injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40